Search results

3936 results

Sorted by Relevance . Sort by Date

  1. Hemosep for cell salvage (MIB103)

    MIB103 No intro Summary The technology described in this briefing is Hemosep. It is used for cell salvage and

  2. Mollii suit for spasticity (MIB100)

    Advice on the use of Mollii suit (formerly Elektrodress; a therapeutic electrical stimulation jacket and trousers) for spasticity to aid local decision-making

  3. Hyperhidrosis: oxybutynin (ES10)

    Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making

  4. Renin-angiotensin system drugs: dual therapy (KTT2)

    The key therapeutic topic renin-angiotensin system drugs: dual therapy has been retired from the 2017 update of medicines optimisation: key therapeutic topics. The version published in 2016 is available here for information but it has not been updated since February 2016. Like all the other key therapeutic topics it is not formal NICE guidance .

  5. InterDry for intertrigo (MIB192)

    Advice on the use of InterDry for intertrigo (inflammatory skin rash) to aid local decision making

  6. Antimicrobial stewardship: prescribing antibiotics (KTT9)

    This document summarises the evidence base on antimicrobial stewardship: prescribing antibiotics . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

  7. Antipsychotics in people living with dementia (KTT7)

    This document summarises the evidence base on antipsychotics in people living with dementia . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

  8. Hypnotics (KTT6)

    This document summarises the evidence base on hypnotics . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

  9. Asthma: medicines safety priorities (KTT5)

    This document summarises the evidence base on asthma: medicines safety priorities . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

  10. Lipid-modifying drugs (KTT3)

    This key therapeutic topic has been reincluded in the September 2019 update of medicines optimisation: key therapeutic topics. This document summarises the evidence base on lipid-modifying drugs. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

  11. Shared decision making (KTT23)

    This document summarises the evidence base on shared decision making . It is a key therapeutic topic that has been identified to support Medicines Optimisation. It is not formal NICE guidance .

  12. Chemotherapy dose standardisation (KTT22)

    This document summarises the evidence base on chemotherapy dose standardisation . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

  13. Medicines optimisation in chronic pain (KTT21)

    This document summarises the evidence base on medicines optimisation in chronic pain . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

  14. Safer insulin prescribing (KTT20)

    This document summarises the evidence base on safer insulin prescribing . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .

  15. Multimorbidity and polypharmacy (KTT18)

    This document summarises the evidence base on multimorbidity and polypharmacy . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .